EcoDrugPlus

Probable Histone Deacetylase 1-B

Ensembl ID : ENSSDUG00000001669
Gene Symbol: LOC111233164
3 Cross references
250 Possible Orthologues:

Progesterone Receptor

Ensembl ID : ENSSDUG00000019094
Gene Symbol: PGR
3 Cross references
193 Possible Orthologues:

Prostaglandin D2 Receptor 2

Ensembl ID : ENSSDUG00000019777
Gene Symbol: PTGDR2
2 Cross references
135 Possible Orthologues:

Prostaglandin D2 Receptor 2

Ensembl ID : ENSSDUG00000019401
Gene Symbol: PTGDR2
1 Cross references
145 Possible Orthologues:

Prostaglandin E Receptor 2a (Subtype Ep2)

Ensembl ID : ENSSDUG00000010181
Gene Symbol: PTGER2A
1 Cross references
202 Possible Orthologues:

Prostaglandin E Receptor 3

Ensembl ID : ENSSDUG00000004455
Gene Symbol: PTGER3
3 Cross references
194 Possible Orthologues:

Prostaglandin E2 Receptor Ep1 Subtype-Like

Ensembl ID : ENSSDUG00000008765
Gene Symbol: LOC111223722
3 Cross references
164 Possible Orthologues:

Prostaglandin E2 Receptor Ep1 Subtype-Like

Ensembl ID : ENSSDUG00000019976
Gene Symbol: LOC111229309
3 Cross references
167 Possible Orthologues:

Prostaglandin E2 Receptor Ep2 Subtype-Like

Ensembl ID : ENSSDUG00000001016
Gene Symbol: LOC111236052
3 Cross references
170 Possible Orthologues:

Prostaglandin E2 Receptor Ep4 Subtype-Like

Ensembl ID : ENSSDUG00000008343
Gene Symbol: LOC111237362
3 Cross references
201 Possible Orthologues:

Prostaglandin E2 Receptor Ep4 Subtype-Like

Ensembl ID : ENSSDUG00000001875
Gene Symbol: LOC111230871
3 Cross references
202 Possible Orthologues:

Prostaglandin F Receptor

Ensembl ID : ENSSDUG00000006992
Gene Symbol: PTGFR
3 Cross references
195 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).